Third-line Treatment
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients (NCT05426811) | China Medical University, China | 2022-07-01 |
Track Third-line Treatment automatically
Every clearance here is in the API, with alerts when new ones post.